{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:27:32Z","timestamp":1781018852936,"version":"3.54.1"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/coc.0b013e318277d5c8","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T08:15:53Z","timestamp":1355386553000},"page":"261-265","source":"Crossref","is-referenced-by-count":9,"title":["Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma"],"prefix":"10.1097","volume":"37","author":[{"given":"Gautam","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Curtsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew F.","family":"Mescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz Z.","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CMR.0b013e328346554d","article-title":"Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials.","volume":"21","author":"Chi","year":"2011","journal-title":"Melanoma Res"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.4049\/jimmunol.149.7.2402","article-title":"Surface contact requirements for activation of cytotoxic T lymphocytes.","volume":"149","author":"Mescher","year":"1992","journal-title":"J Immunol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4049\/jimmunol.149.1.269","article-title":"Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen.","volume":"149","author":"Rogers","year":"1992","journal-title":"J Immunol"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2307\/2531201","article-title":"Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.","volume":"42","author":"Lachin","year":"1986","journal-title":"Biometrics"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4049\/jimmunol.170.1.228","article-title":"In vivo augmentation of tumor-specific CTL responses by class Ipeptide antigen complexes on microspheres (large multivalent immunogen).","volume":"170","author":"Goldberg","year":"2003","journal-title":"J Immunol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e318277d5c8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T19:11:51Z","timestamp":1687893111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201406000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e318277d5c8","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}